Stock Analysis on Net

Abbott Laboratories (NYSE:ABT)

$24.99

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
Quarterly Data

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Abbott Laboratories, common-size consolidated balance sheet: liabilities and stockholders’ equity (quarterly data)

Microsoft Excel
Dec 31, 2025 Sep 30, 2025 Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Short-term borrowings
Trade accounts payable
Salaries, wages and commissions
Other accrued liabilities
Dividends payable
Income taxes payable
Current portion of long-term debt
Current liabilities
Long-term debt, excluding current portion
Post-employment obligations, deferred income taxes and other long-term liabilities
Long-term liabilities
Total liabilities
Preferred shares, one dollar par value, none issued
Common shares, without par value, issued at stated capital amount
Common shares held in treasury, at cost
Earnings employed in the business
Accumulated other comprehensive loss
Total Abbott shareholders’ investment
Noncontrolling interests
Total shareholders’ investment
Total liabilities and shareholders’ investment

Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).


The composition of liabilities and shareholders’ equity at the company exhibits several notable trends over the observed period from March 2021 to December 2025. Overall, there is a shift in the balance between liabilities and shareholders’ equity, with a notable increase in the proportion represented by shareholders’ equity, particularly towards the end of the period.

Current Liabilities
Current liabilities, as a percentage of total liabilities and shareholders’ investment, generally increased from 17.12% in March 2021 to a peak of 20.81% in December 2022. Subsequently, they decreased to 19.02% by September 2023, before rising again to 19.84% in March 2024. A final decline is observed, reaching 17.32% by December 2025. Within current liabilities, trade accounts payable remained relatively stable, fluctuating between approximately 5.5% and 6.5% for most of the period, with a gradual decline to 4.89% by December 2025. Salaries, wages, and commissions show a cyclical pattern, peaking in the latter half of each year, and generally increasing over time, reaching 2.01% in September 2023 before decreasing to 2.06% in September 2025. Income taxes payable also demonstrate seasonality, with increases towards the end of the year, and a notable increase to 0.67% in December 2023, before decreasing to 0.66% in September 2025. The current portion of long-term debt experienced a significant increase in late 2022 and early 2023, peaking at 3.10% in March 2022, before declining substantially to 1.60% in September 2025.
Long-Term Liabilities
Long-term liabilities decreased steadily from 36.46% in March 2021 to 20.12% in December 2025. Long-term debt, excluding the current portion, followed a similar downward trend, decreasing from 24.03% to 11.41% over the same period. Post-employment obligations, deferred income taxes, and other long-term liabilities also decreased, though less dramatically, from 12.43% to 8.71%.
Shareholders’ Equity
Total shareholders’ equity increased from 46.42% in March 2021 to 60.86% in December 2025. Common shares issued at stated capital amount remained relatively stable between 30% and 34% until 2024, when it began a decline to 29.44% by December 2025. Common shares held in treasury consistently represented a negative percentage, increasing in magnitude from -13.53% to -22.16% before decreasing to -19.81% by December 2025. Earnings employed in the business showed a consistent increase, rising from 39.39% to 58.33% in September 2025, before decreasing slightly to 57.41% in December 2025. Accumulated other comprehensive loss remained negative throughout the period, but its impact lessened over time, moving from -12.76% to -6.92%. Noncontrolling interests remained relatively small, fluctuating around 0.3%, with a slight increase to 0.74% in December 2025.

The observed trends suggest a strategic shift towards financing through equity rather than debt. The reduction in long-term liabilities, coupled with the increase in retained earnings and common shares, indicates a strengthening financial position. The fluctuations in current liabilities appear to be driven by seasonal factors and changes in working capital management. The increasing proportion of earnings employed in the business suggests effective capital allocation and profitability.